Our meta-analysis also demonstrated that the use of SGLT2i as an add-on therapy was associated with long-term risks in the incidence of ketone-related SAEs and DKA in T1DM patients receiving insulin therapy. Here, INS is linked to type 1 diabetes mellitus.